Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis

Cancer Cell

Volumn 15, Issue 1, 2009, Pages 57-66

  Fotheringham, Susan ^a   Epping, Mirjam T ^b   Stimson, Lindsay ^a   Khan, Omar ^a   Wood, Victoria ^a   Pezzella, Francesco ^c   Bernards, René ^b   La Thangue, Nicholas B ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

CELLBIO; HUMDISEASE; SIGNALING

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; BLEOMYCIN; ETOPOSIDE; HR23B ENZYME; PROTEASOME; SMALL INTERFERING RNA; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG SENSITIVITY; EMBRYO; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MOUSE; MULTIPLE MYELOMA; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; SEZARY SYNDROME; T CELL LYMPHOMA;

EID: 58049208190     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2008.12.001     Document Type: Article

References (26)

1. Bence N.F., Sampat R.M., and Kopito R.R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292 (2001) 1552-1555
2. Berns K., Hijmans E.M., Mullenders J., Brummelkamp T.R., Velds A., Heimerikx M., Kerkhoven R.M., Madiredjo M., Nijkamp W., Weigelt B., et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428 (2004) 431-437
3. Bolden J.E., Peart M.J., and Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5 (2006) 769-784
4. Carey N., and La Thangue N.B. Histone deacetylase inhibitors: gathering pace. Curr. Opin. Pharmacol. 6 (2006) 369-375
5. Chan H.M., and La Thangue N.B. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J. Cell Sci. 114 (2001) 2363-2373
6. Chen L., and Madura K. Rad23 promotes the targeting of proteolytic substrates to the proteasome. Mol. Cell. Biol. 22 (2002) 4902-4913
7. Chen L., Shinde U., Ortolan T.G., and Madura K. Ubiquitin-associated (UBA) domains in Rad23 bind ubiquitin and promote inhibition of multi-ubiquitin chain assembly. EMBO Rep. 2 (2001) 933-938
8. Duvic M., and Zhang C. Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma. Br. J. Cancer 95 Suppl 1 (2006) S13-S19
9. Fujiwara K., Tenno T., Sugasawa K., Jee J.G., Ohki I., Kojima C., Tochio H., Hiroaki H., Hanaoka F., and Shirakawa M. Structure of the ubiquitin-interacting motif of S5a bound to the ubiquitin-like domain of HR23B. J. Biol. Chem. 279 (2004) 4760-4767
10. Gilon T., Chomsky O., and Kulka R.G. Degradation signals for ubiquitin system proteolysis in Saccharomyces cerevisiae. EMBO J. 17 (1998) 2759-2766
11. Hiyama H., Yokoi M., Masutani C., Sugasawa K., Maekawa T., Tanaka K., Hoeijmakers J.H., and Hanaoka F. Interaction of hHR23 with S5a. The ubiquitin-like domain of hHR23 mediates interaction with S5a subunit of 26 S proteasome. J. Biol. Chem. 274 (1999) 28019-28025
12. Inche A.G., and La Thangue N.B. Chromatin control and cancer-drug discovery: realizing the promise. Drug Discov. Today 11 (2006) 97-109
13. Khan O., and La Thangue N.B. Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas. Nat. Clin. Pract. Oncol. 5 (2008) 714-726
14. Li L., Bales E.S., Peterson C.A., and Legerski R.J. Characterization of molecular defects in xeroderma pigmentosum group C. Nat. Genet. 5 (1993) 413-417
15. Mann B.S., Johnson J.R., Cohen M.H., Justice R., and Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12 (2007) 1247-1252
16. Marks P.A., and Jiang X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 4 (2005) 549-551
17. Marks P.A., and Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat. Biotechnol. 25 (2007) 84-90
18. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6 (2006) 38-51
19. Nalepa G., Rolfe M., and Harper J.W. Drug discovery in the ubiquitin-proteasome system. Nat. Rev. Drug Discov. 5 (2006) 596-613
20. Ng J.M., Vrieling H., Sugasawa K., Ooms M.P., Grootegoed J.A., Vreeburg J.T., Visser P., Beems R.B., Gorgels T.G., Hanaoka F., et al. Developmental defects and male sterility in mice lacking the ubiquitin-like DNA repair gene mHR23B. Mol. Cell. Biol. 22 (2002) 1233-1245
21. Richardson P.G., Mitsiades C., Hideshima T., and Anderson K.C. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu. Rev. Med. 57 (2006) 33-47
22. Richon V.M. Cancer biology: mechanism of antitumour action of vorinostat (suberolyanilide hydroxamic acid), a novel deacetylase inhibitor. Br. J. Cancer 95 Suppl 1 (2006) S2-S6
23. Schauber C., Chen L., Tongaonkar P., Vega I., Lambertson D., Potts W., and Madura K. Rad23 links DNA repair to the ubiquitin/proteasome pathway. Nature 391 (1998) 715-718
24. Sugasawa K., Ng J.M., Masutani C., Maekawa T., Uchida A., van der Spek P.J., Eker A.P., Rademakers S., Visser C., Aboussekhra A., et al. Two human homologs of Rad23 are functionally interchangeable in complex formation and stimulation of XPC repair activity. Mol. Cell. Biol. 17 (1997) 6924-6931
25. Wilkinson C.R., Seeger M., Hartmann-Petersen R., Stone M., Wallace M., Semple C., and Gordon C. Proteins containing the UBA domain are able to bind to multi-ubiquitin chains. Nat. Cell Biol. 3 (2001) 939-943
26. Xu W.S., Parmigiani R.B., and Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26 (2007) 5541-5552